Quest Diagnostics Inc hits a 20-day low amid market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 Dec 25
Source: Coinmarketcap
Quest Diagnostics Inc experienced a price decline of 3.01%, hitting a 20-day low during regular trading hours.
This drop is attributed to sector rotation, as the broader market showed mixed signals with the Nasdaq-100 up 0.28% and the S&P 500 down 0.16%. The divergence in performance indicates that investors are reallocating their portfolios, impacting stocks like Quest Diagnostics.
The implications of this movement suggest that investors may be shifting their focus away from healthcare stocks, which could affect Quest Diagnostics' future performance unless there are significant developments or news to reverse this trend.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 203.75 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 182.350
Low
190.00
Averages
203.75
High
215.00
Current: 182.350
Low
190.00
Averages
203.75
High
215.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
